Clinical Trials Logo

Malignant Rhabdoid Tumors (MRT) clinical trials

View clinical trials related to Malignant Rhabdoid Tumors (MRT).

Filter by:
  • None
  • Page 1

NCT ID: NCT02601950 Completed - Synovial Sarcoma Clinical Trials

A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

Start date: December 22, 2015
Phase: Phase 2
Study type: Interventional

This study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments. Soft tissue cancers are rare and can occur almost anywhere in the body. Part 1 of this trial will study the safety and the level that adverse effects of the study drug tazemetostat in combination with doxorubicin (current front line treatment) can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for the next part of the study. Part 2 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug plus doxorubicin versus doxorubicin plus placebo (dummy treatment).

NCT ID: NCT01747876 Terminated - Neuroblastoma Clinical Trials

Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

Start date: May 28, 2013
Phase: Phase 1
Study type: Interventional

LEE011 is a small molecule inhibitor of CDK4/6. LEE011 has demonstrated in vitro and in vivo activity in both tumor models. The primary purpose of this study was to determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) in pediatric patients and to delineate a clinical dose to be used in future studies. This study was also to have assessed the safety, tolerability, PK and preliminary evidence of antitumor activity of LEE011 in patients with MRT or neuroblastoma.